Viz.ai and UTMB Announce Collaboration to Accelerate Recruitment in the CHESS Study with Viz Subdural Solution

AI-powered care coordination to help increase enrollment rates and reduce time to randomization in chronic subdural hematoma

SAN FRANCISCO–(BUSINESS WIRE)–#ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and the University of Texas Medical Branch at Galveston (UTMB), an academic health institution of The University of Texas System, have announced a collaboration to incorporate Viz Subdural software into the Chronic Subdural Hematoma Treatment with Embolization Versus Surgery Study (CHESS).1


A chronic subdural hematoma (cSDH) is an old clot of blood on the surface of the brain beneath its outer covering. These liquefied clots most often occur in patients aged 60 and older who have brain atrophy, a shrinking or wasting away of brain tissue due to age or disease.2 As the population ages, cSDH is predicted to be the most common cranial neurosurgical condition by 2030.3 CHESS will collect safety and efficacy data in patients with a moderately symptomatic convexity cSDH.

“CHESS is designed to be the first US randomized controlled trial to provide evidence on the safety and efficacy of standalone middle meningeal artery embolization (MMAE) vs surgical drainage using particle embolization,” said Peter Kan, MD, MPH, FRCSC, FAANS, Professor and Chair, Department of Neurosurgery, University of Texas Medical Branch. “Viz.ai’s Subdural tool holds the promise of efficiently identifying prospective participants, thereby aiding in the timely completion of this important trial.”

The Viz Subdural algorithm was approved in 2022 as the first SDH-specific AI-powered detection and care coordination platform with the ability to identify suspected cases of acute and chronic subdural bleeds, and then quickly notify the care team to review the patient case and make a treatment decision if necessary. In the CHESS trial, Viz.ai will notify investigators immediately when it detects a patient who has suspected SDH and meets the eligibility criteria for enrollment. Study investigators can measure chronic bleeds4 and coordinate subject enrollment easily and securely through Viz.ai’s dynamic, mobile, HIPAA-compliant platform.

“Patient enrollment is the most time-consuming and costly aspect of the clinical trial process,” said Prem Batchu-Green, Vice President of Clinical at Viz.ai. “By deploying Viz.ai for the CHESS study, we are not only reducing the manual burden of patient identification on research staff but also improving SDH detection and workflow as well as increasing SDH awareness, physician engagement, clinical specialist attendance, and case collaboration.”

1 The study was funded by the National Institute of Neurological Disorders and Stroke, of the National Institutes of Health, under grant award number 1UG3NS128397-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

2 Chronic subdural hematomas. UCLA Health. (n.d.). https://www.uclahealth.org/medical-services/neurosurgery/conditions-treated/chronic-subdural-hematomas

3 Hoffman et al. (n.d.). Management of chronic subdural hematoma with the subdural evacuating port system: Systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/33775320/

4 Viz Subdural is currently available commercially for triage and notification. Measuring SDH is not available for commercial use.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Olivia Schlabach

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.